| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
TOKYO—Eisai Co. Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland regarding proteolysis targeting chimeras (PROTACs) with an eye toward drug discovery in oncology area.
 
PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an ubiquitin ligase (E3 ligase) and another that binds to a target protein meant for degradation. They work by recruiting an E3 ligase to tag the target protein for ubiquitination for degradation through the intracellular degradation system. It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.
 
In this collaboration research, Prof. Alessio Ciulli of the University of Dundee’s School of Life Sciences, who is one of the global pioneers in the field of PROTACs research, is responsible for directing the research.
 
The collaboration combines the world-leading expertise and technology of the Ciulli laboratory in PROTACs research with Eisai's discovery research and clinical development experience in the oncology area. Under this agreement, Eisai has the option rights to develop and commercialize the compounds resulted from this collaboration research.

Related Topics

Published In

Volume 15 - Issue 9 | September 2019

September 2019

September 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue